In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Multidisciplinary care for end-stage HF. How to improve care?

Session Poster Session 4

Speaker Paula Fluvia

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Multidisciplinary Interventions
  • Session type : Poster Session

Authors : P Fluvia (Girona,ES), S Mirabet Perez (Barcelona,ES), A Pascual Lopez (Barcelona,ES), MJ Pirla (Barcelona,ES), N Mesado Batalla (Barcelona,ES), I Lumillo Gutierrez (Barcelona,ES), E Roig Minguell (Barcelona,ES)

P Fluvia1 , S Mirabet Perez2 , A Pascual Lopez2 , MJ Pirla2 , N Mesado Batalla2 , I Lumillo Gutierrez2 , E Roig Minguell2 , 1University Hospital de Girona Dr. Josep Trueta, Cardiology - Girona - Spain , 2Hospital de la Santa Creu i Sant Pau - Barcelona - Spain ,


Palliative care in advanced heart failure (HF) patients is not standardized. Several trials have demonstrated the usefulness of starting palliative care along with cardiac treatment in the final stages of the disease

 Purpose: Assess the feasibility of a multidisciplinary team in patients with advanced HF.

 Material and methods: Observational, prospective, single-center study performed in outpatients with advanced HF excluded for heart transplantation or LVAD. The multidisciplinary team includes a cardiologist and nurse specialized in advanced HF, a palliative care physician, case manager nurses and primary care physicians.

Patients were identified as palliative according to the clinical clues reported in 2013 ACC/AHA guidelines. All patients and their relatives accepted to be included in the program. 

We evaluated the level of knowledge of the end-stage phase of the disease, the main non-cardiovascular symptoms and treatments, number of hospital admissions, time to death and place of death. 

 Results: From October 2016 to March 2018, 23 patients were included. Age 77 ± 5 years, 92% men. Most of them had high comorbidity (Barthel 78.6 ± 15 ) and some degree of dependency (Charlson 6 ± 1.1). Ten patients had HFpEF.

All patients knew the severity of their illness and 65% considered the possibility of dying soon. 

More than 70% of the patients had non cardiovascular symptoms. The main symptoms and palliative treatments are shown in Figure 1 and 2. 

During a mean follow-up of  4±2 months,  7 patients (30%)  were admitted (4 patients for cardiovascular (CV) problems and 3 for non-cardiovascular) and 16 patients died (14 CV deaths and 2 non-CV). Of those, twelve patients (75%) died at home or in long-stay centers. 

 Conclusion: In our experience the multidisciplinary care for end-stage HF was feasible and well accepted for the patients and their relatives. Most of them knew the severity of the disease and the poor prognosis. 

The majority of patients received treatments for non-cardiovascular symptoms, being the multidisciplinary palliative care useful for the management of these patients. 

A high percentage of patients died outside the hospital. The high short-term mortality probably suggests that palliative care should be considered earlier in end-stage HF.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are